Glastonbury, CT, United States of America

Qiufen May Xue

This inventor holds 38 USPTO granted patents and 17 published patent applications, plus 1 CIPO patent and 16 EPO patents, primarily in Cancer Therapeutics. Top assignees: Amgen Inc., Bristol-Myers Squibb Compnay. Active years: 2002-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Qiufen May Xue. Retrieved from https://idiyas.com/inventor/qiufen-may-xue

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 38 (Patent Applications = 17)

% Patents Active = 92.1

CIPO Patents = 1 (Patent Applications = 5)

EPO Patents = 16 (Patent Applications = 17)

Average Co-Inventor Count = 11.2

ph-index = 9

Forward Citations = 244(Granted Patents)

Location History:

Glastonbury, CT (US) (2002 - 2005)
Newbury Park, CA (US) (2005 - 2017)
Thousand Oaks, CA (US) (2008 - 2024)

Company Filing History:

Bristol-Myers Squibb Compnay

patents

Years Active: 2002-2026

Loading Chart...

Areas of Expertise:

KIF18A Inhibitors

KRAS G12C Inhibitors

Beta-Secretase Modulators

Pharmaceutical Formulations

Spiro-Tetracyclic Compounds

Indole Derivatives

Piperazine Derivatives

Antiviral Activity

Amino-Heteroaryl Compounds

Dihydrothiazine Compounds

Cyclopropyl Fused Compounds

Taxane Anticancer Agents

38 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12540129 - KIF18A inhibitors (2026-02-03),

2. 12459932 - KIF18A inhibitors (2025-11-04),

3. 12441736 - KIF18A inhibitors (2025-10-14),

4. 12440491 - KRAS G12C inhibitors and methods of using the same (2025-10-14),

5. 12435058 - KIF18A inhibitors (2025-10-07),

6. 12083121 - Substituted piperazines as KRAS G12C inhibitors (2024-09-10),

7. 11766436 - KRAS G12C inhibitors and methods of using the same (2023-09-26),

8. 11285156 - Substituted piperazines as KRAS G12C inhibitors (2022-03-29),

9. 11090304 - KRAS G12C inhibitors and methods of using the same (2021-08-17),

10. 9777019 - Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use (2017-10-03),

11. 9611261 - Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use (2017-04-04),

12. 9556135 - Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use (2017-01-31),

13. 9550762 - Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use (2017-01-24),

14. 9296759 - Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use (2016-03-29),

15. 9296734 - Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use (2016-03-29),

Title: The Innovative Contributions of Qiufen May Xue

Introduction: Qiufen May Xue, based in Glastonbury, Connecticut, is a prominent inventor with an impressive portfolio of 33 patents. His work primarily focuses on the development of pharmaceutical treatments, significantly impacting the field of cancer therapy.

Latest Patents: Among his numerous inventions, Qiufen May Xue's latest patents include innovative compounds designed as KRAS G12C inhibitors. These KRAS G12C inhibitors, detailed in his patent applications, are vital for treating various disorders, particularly pancreatic, colorectal, and lung cancers. The compositions and methods outlined in these patents offer potential breakthroughs in the fight against these challenging diseases.

Career Highlights: Throughout his career, Qiufen May Xue has worked with renowned companies in the biotechnology sector, including Amgen Inc. and Bristol-Myers Squibb Company. His contributions to these organizations have helped propel advancements in drug development and therapeutic solutions.

Collaborations: Qiufen has collaborated with esteemed colleagues, including Patricia Lopez and Yuan Cheng. These partnerships have facilitated innovative research and development, further enhancing the impact of his work in the scientific community.

Conclusion: Qiufen May Xue's dedication to innovation in pharmaceuticals is evident through his extensive patent portfolio and collaborative efforts. His ongoing contributions to the field of cancer treatment underscore the importance of continued research and innovation in improving healthcare outcomes.

Profile summary based on public USPTO records.